Richard Gallagher | Sep 1, 2002 | 2 min read
Self-renewal and the capacity to differentiate into a multitude of mature cell types have made stem cells the hottest ticket in biomedicine. But there are questions aplenty, scientific and otherwise. Do we need more stem cell lines? President Bush may believe that the available lines are sufficient, but these are derived fro1m blastocysts produced in fertility clinics. Maximizing the impact of stem cells in medicine calls for new lines derived from specific diseases, like cancers. Must thera